Lead Product(s): Pentosan Polysulfate Sodium
Therapeutic Area: Musculoskeletal
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bell Potter Securities
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2020
Proceeds will be applied to costs of the second phase 3 osteoarthritis (OA) clinical trial and leaves Paradigm fully-funded through to completion of this trial.